Study:
Phase III Trial of Continuous Schedule AC + G vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer
Rationale:
Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and
paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or
die. Combining more than one drug and giving them after surgery may kill any remaining tumor
cells. It is not yet known which combination chemotherapy regimen is more effective in
treating resected breast cancer.
Purpose:
This randomized phase III trial is comparing 2 different regimens of combination
chemotherapy to see how well they work in treating patients who have undergone surgery for
stage I, stage II, or stage III breast cancer.
Study Status: Active, not recruiting
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Breast Cancer |
Biological: pegfilgrastim
Drug: AC regimen
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: paclitaxel |
Phase 3 |
Verified by
Southwest Oncology Group
January, 2012
Sponsored by: Southwest Oncology Group
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00070564
Study Type: Interventional
Study Design: Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Beachwood Family Health and Surgery Center
Beachwood, Ohio 44122
United States
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
Cleveland Clinic Cancer Center at Fairview Hospital
Cleveland, Ohio 44111
United States
Cleveland Clinic Cancer Center
Independence, Ohio 44131
United States
Cleveland Clinic Foundation - Strongsville
Strongsville, Ohio 44136
United States
Cleveland Clinic - Wooster
Wooster, Ohio 44691
United States
George Thomas Budd, MD.,
Halle C.F. Moore, MD.,